Jul 22, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Coca-Cola’s (KO) Q2 2025 earnings call.
Coca-Cola (KO) is the world’s largest beverage company, selling over 200 brands across more than 200 countries and territories. Best known for its flagship Coca-Cola soft drink, the company also owns a broad portfolio that spans sparkling beverages, water, sports drinks, juices, dairy, and ready-to-drink coffees and teas. KO delivered 5% organic revenue growth and 4% EPS growth in Q2 despite a 1% volume decline and 5% FX headwinds. Performance varied by region: the US and Europe rebounded, while India and Mexico faced weather disruptions and geopolitical pressures. Fairlife saw strong demand but remains capacity-constrained until a new US facility opens in 2026. The company leaned into affordability with refillables and mini cans, while continuing to scale marketing innovation globally. Coke Zero Sugar, Sprite, and localized campaigns like “Share a Coke” drove share gains. The US Coca-Cola variety sweetened with cane sugar set for release this fall was also discussed. The stock fell as much as 1.1% on 7/22 despite beats on the top and bottom lines…
Continue reading our Conference Call Recap for KO by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Jul 22, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Equifax’s (EFX) Q2 2025 earnings call.
Equifax (EFX) is a data, analytics, and technology company best known for its credit bureau services, but its reach extends into employment, income, identity, and fraud verification. Through platforms like The Work Number (TWN), Equifax offers real-time employment data, enabling government agencies, banks, auto lenders, and employers to make faster, more informed decisions. With its US cloud transformation complete, the company has built a modern infrastructure for multi-data solutions that combine credit, income, and alternative data. Its scale and regulatory relationships give it unique insight into consumer behavior, hiring trends, state budget dynamics, and credit market activity. The company’s earnings call spotlighted a growing divide between short-term government headwinds and long-term optimism, with One Big Beautiful Bill Act (OBBBA)-related requirements and IRS EITC (Earned Income Tax Credit) fraud detection driving a bullish long-range view. Mortgage revenue rose 20% despite 8.5% lower inquiry volumes, buoyed by strong pricing and TWN-enhanced preapproval products. Talent Solutions remained soft as corporate hiring slowed and job churn stayed low. The cloud-powered innovation engine is clearly working: US Information Services hit a 10% new product vitality rate, and international markets are seeing margin lift from efficiency gains. Caution around tariffs and economic uncertainty kept the second-half guide more subdued despite solid YTD results, and the stock fell as much as 7.3% on 7/22…
Continue reading our Conference Call Recap for EFX by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Jul 21, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Domino’s Pizza (DPZ) Q2 2025 earnings call.
Domino’s Pizza (DPZ) is the largest pizza company in the world by global retail sales, operating a heavily franchised model across more than 90 markets. Known for its delivery and carryout focus, the company produces and sells a range of pizzas, pastas, chicken, and side items through its extensive store network. Domino’s is a case study in digital transformation within QSR, with over 85% of US orders placed digitally and a global supply chain that supports consistent execution. Domino’s delivered 3.4% US same-store sales growth in Q2, driven by strong traction from the launch of Parmesan-Stuffed Crust, its most complex product yet. The company completed its nationwide rollout on DoorDash and expects it to be a meaningful comp driver in the second half of the year, joining Uber Eats to round out its aggregator strategy. Carryout growth hit a record 5.8%, boosted by its revamped Domino’s Rewards program. Executives emphasized Domino’s positioning to win on value during a pressured consumer backdrop. Global net store growth totaled 178, including 30 in the US, with strong performance in India and Canada helping offset macro risks abroad. DPZ shares opened 4.5% higher on 7/21, but gains were completely wiped out intraday after missing estimates on the top and bottom lines…
Continue reading our Conference Call Recap for DPZ by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Jul 21, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers American Express’ (AXP) Q2 2025 earnings call.
American Express (AXP) is a global payments company best known for its premium charge and credit cards, financial services, and travel-related offerings. It issues cards, operates a proprietary merchant network, and earns revenue from both card fees and discount rates on transactions. The company gives unique insight into discretionary consumer spending, especially among younger, high-income, and international segments. AXP reported record revenue of $17.9B (+9% YoY) and EPS of $4.08 (+17% YoY ex-Accertify). Gen-Z and Millennial spend surged 40% and 10% respectively, and transaction growth held strong at +9%. Despite softening in airline and lodging categories, overall cardmember spend remained resilient. The upcoming US Platinum card refresh was a major theme, with AXP reaffirming its leadership in the premium space and defending its pricing power amid rising competition. The company also discussed exiting its Amazon and Lowe’s co-brand portfolios, double-digit international growth, and early moves in digital currency through a new Coinbase partnership. The stock declined 2.4% on 7/18 despite better-than-expected results…
Continue reading our Conference Call Recap for AXP by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Jul 21, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers 3M’s (MMM) Q2 2025 earnings call.
3M is a global industrial and technology company known for its diversified portfolio spanning over 60,000 products across safety, healthcare, consumer goods, electronics, and manufacturing. It serves a range of customers, from hospitals and governments to contractors and big-box retailers, offering everything from adhesives and abrasives to air filtration and medical tapes. What makes 3M impressive is its relentless focus on applied science and operational scale, launching 126 new products in the first half of 2025 alone. The company provides unique insights into global industrial trends, supply chain dynamics, and innovation-led margin expansion. 3M delivered strong Q2 results, with adjusted EPS of $2.16 (+12% YoY) and free cash flow of $1.3B. Key drivers included a 70% YoY increase in product launches (64 in Q2), expansion of a global commercial excellence initiative, and operational improvements. The macro backdrop remains “sluggish,” but 3M sees momentum from internal execution, particularly in industrial, auto, and electrical markets. Tariff impacts are now baked into guidance, offset by pricing power and sourcing changes. Full-year EPS guidance was raised to $7.75–$8.00, with margin expansion and >100% free cash flow conversion expected. In reaction to earnings on 7/18, shares of MMM traded down 3.7%…
Continue reading our Conference Call Recap for MMM by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
Jul 18, 2025
Bespoke’s Conference Call Recaps use AI to summarize lengthy earnings calls. The commentary below is AI-generated and then edited by Bespoke for quality control. As always, none of these summaries should be construed as recommendations to buy or sell any securities, and investors should do their own research and/or consult with a financial professional before making any investment decisions.
Our latest recap available to Bespoke subscribers covers Johnson & Johnson’s (JNJ) Q2 2025 earnings call.
Johnson & Johnson is a global healthcare powerhouse operating across innovative medicine and med-tech, uniquely positioned as the only major company with leadership in both sectors. It develops oncology treatments (like DARZALEX for multiple myeloma and RYBREVANT/LAZCLUZE for lung cancer), immunology therapies (such as TREMFYA for psoriasis and IBD), CNS drugs (like SPRAVATO for depression and CAPLYTA for bipolar disorder), and cutting-edge surgical and cardiovascular devices. J&J also integrates device and drug innovation, exemplified by TAR-200, a bladder cancer drug-releasing system, and OTTAVA, its robotic surgery platform. The company serves patients globally, with a deep R&D pipeline and $55B US investment plan shaping the future of medicine. In Q2, J&J reported 4.6% operational sales growth, raising its 2025 guidance by $2B. Despite biosimilar erosion of STELARA, growth surged in oncology driven by CARVYKTI (CAR-T therapy), TECVAYLI and TALVEY (multiple myeloma bispecifics), and TAR-200’s FDA priority review. TREMFYA expanded in Inflammatory Bowel Disease, and SPRAVATO (+53%) and CAPLYTA led neuroscience. MedTech shined with Abiomed (heart pumps), Shockwave IVL (vascular plaque treatment), and VARIPULSE (cardiac ablation). Guidance rose on FX tailwinds, strong pipeline momentum, and MedTech acceleration…
Continue reading our Conference Call Recap for JNJ by becoming a Bespoke Institutional subscriber. You can sign up for Bespoke Institutional now and receive a 14-day trial to read our newest Conference Call Recap. To sign up, choose either the monthly or annual checkout link below:
Bespoke Institutional – Monthly Payment Plan
Bespoke Institutional – Annual Payment Plan
